Payment overview · 2025
General Payments
$312.69
29 reported records · 7 companies
Healthcare provider profile · identity verified
Jacques Txuj Ci Moua, MD
Allopathic & Osteopathic Physicians|Family Medicine · HICKORY, NC · NPI 1992931737
Verified facts
What the public records show
CMS Open Payments records show Jacques Txuj Ci Moua, MD received $312.69 in general payments during 2025 across 29 reported records.
ABBVIE INC. accounted for 46.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Linzess by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $145.68 | 46.6% | 20 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $54.79 | 17.5% | 3 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $40.75 | 13.0% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $23.84 | 7.6% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $19.06 | 6.1% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $16.97 | 5.4% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $11.60 | 3.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $312.69 | 29 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $86.80 | 17 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $58.88 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $58.88 | 3 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $54.79 | 3 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $40.75 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $23.84 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $19.06 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $16.97 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $16.97 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $11.60 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 61 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
61 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 595 | 183 |
| Pantoprazole Sodium | Pantoprazole Sodium | 316 | 116 |
| Amlodipine Besylate | Amlodipine Besylate | 305 | 100 |
| Losartan Potassium | Losartan Potassium | 302 | 103 |
| Lisinopril | Lisinopril | 286 | 96 |
| Metformin Hcl | Metformin Hcl | 220 | 70 |
| Levothyroxine Sodium | Levothyroxine Sodium | 216 | 66 |
| Gabapentin | Gabapentin | 178 | 65 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 173 | 64 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 166 | 67 |
| Omeprazole | Omeprazole | 155 | 52 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 141 | 37 |
| Hydrochlorothiazide | Hydrochlorothiazide | 140 | 48 |
| Tramadol Hcl | Tramadol Hcl | 126 | 37 |
| Montelukast Sodium | Montelukast Sodium | 122 | 48 |
| Metoprolol Succinate | Metoprolol Succinate | 117 | 40 |
| Escitalopram Oxalate | Escitalopram Oxalate | 96 | 25 |
| Furosemide | Furosemide | 88 | 31 |
| Tresiba Flextouch U-100 | Insulin Degludec | 87 | 25 |
| Allopurinol | Allopurinol | 85 | 30 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 83 | 25 |
| Simvastatin | Simvastatin | 82 | 28 |
| Tizanidine Hcl | Tizanidine Hcl | 82 | 32 |
| Fenofibrate | Fenofibrate | 80 | 26 |
| Potassium Chloride | Potassium Chloride | 79 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 78 | 20 |
| Carvedilol | Carvedilol | 76 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 74 | 25 |
| Lorazepam | Lorazepam | 72 | suppressed |
| Januvia | Sitagliptin Phosphate | 69 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 68 | 24 |
| Jardiance | Empagliflozin | 67 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 67 | 15 |
| Alprazolam | Alprazolam | 66 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 66 | 31 |
| Tamsulosin Hcl | Tamsulosin Hcl | 65 | 23 |
| Ozempic | Semaglutide | 61 | 13 |
| Tradjenta | Linagliptin | 60 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 57 | 11 |
| Famotidine | Famotidine | 56 | 19 |
| Symbicort | Budesonide/Formoterol Fumarate | 56 | 22 |
| Alendronate Sodium | Alendronate Sodium | 54 | 20 |
| Eliquis | Apixaban | 53 | 13 |
| Trazodone Hcl | Trazodone Hcl | 53 | 22 |
| Amoxicillin | Amoxicillin | 51 | 47 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 51 | 20 |
| Prednisone | Prednisone | 50 | 41 |
| Glipizide | Glipizide | 48 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 45 | 16 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 42 | 12 |
| Ezetimibe | Ezetimibe | 42 | 17 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 42 | 25 |
| Azithromycin | Azithromycin | 41 | 35 |
| Ibuprofen | Ibuprofen | 41 | 25 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 40 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 40 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 40 | 12 |
| Tresiba Flextouch U-200 | Insulin Degludec | 39 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 39 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 37 | 13 |
| Meloxicam | Meloxicam | 37 | 14 |
| Lovastatin | Lovastatin | 36 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 36 | suppressed |
| Celecoxib | Celecoxib | 35 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 34 | 30 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 33 | 30 |
| Ondansetron Hcl | Ondansetron Hcl | 33 | 27 |
| Cephalexin | Cephalexin | 32 | 29 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 32 | 11 |
| Metformin Hcl Er | Metformin Hcl | 31 | 11 |
| Nitroglycerin | Nitroglycerin | 31 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 30 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 30 | suppressed |
| Myrbetriq | Mirabegron | 30 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 29 | 26 |
| Breo Ellipta | Fluticasone/Vilanterol | 28 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 28 | 13 |
| Dexlansoprazole Dr | Dexlansoprazole | 28 | suppressed |
| Mirtazapine | Mirtazapine | 28 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 28 | suppressed |
| Spironolactone | Spironolactone | 28 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 27 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 26 | 16 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 22 |
| Quetiapine Fumarate | Quetiapine Fumarate | 25 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 24 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 24 | suppressed |
| Novolog Flexpen | Insulin Aspart | 24 | suppressed |
| Linzess | Linaclotide | 23 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 23 | suppressed |
| Trulicity | Dulaglutide | 23 | suppressed |
| Valsartan | Valsartan | 23 | suppressed |
| Fluconazole | Fluconazole | 22 | 14 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 22 | 18 |
| Testosterone Cypionate | Testosterone Cypionate | 22 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 21 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 21 | suppressed |
| Pregabalin | Pregabalin | 21 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 20 | 12 |
| Farxiga | Dapagliflozin Propanediol | 20 | suppressed |
| Mounjaro | Tirzepatide | 20 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Atenolol | Atenolol | 18 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 18 | suppressed |
| Naproxen | Naproxen | 18 | suppressed |
| Nystatin | Nystatin | 18 | suppressed |
| Sucralfate | Sucralfate | 18 | suppressed |
| Veozah | Fezolinetant | 18 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 17 | suppressed |
| Mupirocin | Mupirocin | 17 | suppressed |
| Clonazepam | Clonazepam | 16 | suppressed |
| Glimepiride | Glimepiride | 16 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Primidone | Primidone | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Diazepam | Diazepam | 15 | suppressed |
| Mitigare | Colchicine | 15 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 15 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 14 | 11 |
| Colchicine | Colchicine | 14 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 14 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Epinephrine | Epinephrine | 13 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 13 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 13 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Sotalol | Sotalol Hcl | 12 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 12 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $312.69 · 29 records | ABBVIE INC. | EVENITY, FREESTYLE LIBRE 3, INSPIRE, Omnipod, Ozempic, QULIPTA, Rybelsus, UBRELVY, VOQUEZNA, VRAYLAR | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error